Mostrar registro simples

dc.contributor.authorWagner, Vivian Petersenpt_BR
dc.contributor.authorMartins, Marco Antonio Trevizanipt_BR
dc.contributor.authorMartins, Manoela Dominguespt_BR
dc.contributor.authorWarner, Kristypt_BR
dc.contributor.authorWebber, Liana Pretopt_BR
dc.contributor.authorSquarize, Cristiane Helenapt_BR
dc.contributor.authorNor, Jacques Eduardopt_BR
dc.contributor.authorCastilho, Rogerio Moraespt_BR
dc.date.accessioned2018-10-26T02:43:36Zpt_BR
dc.date.issued2016pt_BR
dc.identifier.issn1949-2553pt_BR
dc.identifier.urihttp://hdl.handle.net/10183/184008pt_BR
dc.description.abstractPatients with mucoepidermoid carcinoma (MEC) experience low survival rates and high morbidity following treatment, yet the intrinsic resistance of MEC cells to ionizing radiation (IR) and the mechanisms underlying acquired resistance remain unexplored. Herein, we demonstrated that low doses of IR intrinsically activated NFκB in resistant MEC cell lines. Moreover, resistance was significantly enhanced in IR-sensitive cell lines when NFκB pathway was stimulated. Pharmacological inhibition of the IKK-β/IκBα/ NFκB axis, using a single dose of FDA-approved Emetine, led to a striking sensitization of MEC cells to IR and a reduction in cancer stem cells. We achieved a major step towards better understanding the basic mechanisms involved in IR-adaptive resistance in MEC cell lines and how to efficiently overcome this critical problem.en
dc.format.mimetypeapplication/pdfpt_BR
dc.language.isoengpt_BR
dc.relation.ispartofOncotarget. Albany. Vol. 7, no. 45 (Nov. 2016), p. 73032-73044pt_BR
dc.rightsOpen Accessen
dc.subjectPatologia bucalpt_BR
dc.subjectNeoplasias bucaispt_BR
dc.titleOvercoming adaptive resistance in mucoepidermoid carcinoma through inhibition of the IKK-β/IκBα/NFκB axispt_BR
dc.typeArtigo de periódicopt_BR
dc.identifier.nrb001059514pt_BR
dc.type.originEstrangeiropt_BR


Thumbnail
   

Este item está licenciado na Creative Commons License

Mostrar registro simples